Allergy-Immunology
Cardiology
Endocrinology
Gastroenterology
General Internal Medicine
Geriatric Medicine
Hematology / Oncology
Hepatology
Hospital Medicine
Immunotherapy
Infectious Diseases
Nephrology / Hypertension
Pulmonary & Critical Care
Rheumatology
Sports Medicine



Publications

Maureen Bolon, MD
Assistant Professor of Medicine

  1. Bolon M, Arnold A, Rehkopf D, Strong E, Feldman H, Goldmann D, Wright S.  Evaluating vancomycin utilization at a pediatric hospital:  new approaches and insights.  Accepted for publication by Infection and Control Hospital Epidemiology March 22, 2004.
  2. Bolon M, Wright S, Gold H, Carmeli Y.  The association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be of lower magnitude than previously published.  Antimicrobial Agents and Chemotherapy 2004 June; 48(6):  1934-40.
  3. Bolon M, Morlote M, Weber S, Koplan B, Wright S, Carmeli Y.  Glycopeptides are no more effective than beta-lactams in preventing surgical site infections following cardiac surgery:  a meta-analysis.  Clinical Infectious Diseases 2004 May; 38(10):  1357-63.

John P. Flaherty, MD
Associate Professor of Medicine

  1. Flaherty JP, Weinstein RA. Nosocomial infection caused by antibiotic-resistant organisms in the intensive care unit. Infect Control Hosp Epidemiol 1996; 17:236-248.
  2. Arnow PA, Flaherty JP. Fever of unknown origin. Lancet 1997; 350:575-580.
  3. Flaherty JP, Chou T, Arnow PA. Infection surveillance and control in the ICU. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care Medicine, 2nd edition. McGraw-Hill, New York, 1998; 35-45.
  4. Sutton S, Flaherty JP. Infections associated with solid tumors. In: Noskin G, ed. Management of Infectious Complications in Cancer Patients. Kluwer Academic Publishers, Norwell, MA, 1998;105-141.
  5. Flaherty JP. Infectious complications of oncologic therapy. In: Vokes EE, Golomb HM, eds. Oncologic Therapies. Springer-Verlag, Berlin, 1999: 228-243.
  6. Linden PK, Moellering RC, Wood C, Rehm S, Flaherty JP, Bompart F, Talbot GH. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-1823.
  7. Gupta S, Flaherty JP, Shaw JC. Erythema nodosum associated with reactivation tuberculous lymphadenitis (scrofula). Int J Derm 2002;41:173-5.
  8. Flaherty JP, Wiener J, Weinstein RA. Chapter 16. Conventional infection control measures: value or ritual?  In:  Infection Control in the ICU Environment (RA Weinstein, MJM Bonten (eds).  Kluwer Academic Publishers, Boston, p.195-211, 2002
  9. Flaherty JP, Stosor V. Non-fermenting gram-negative bacilli.  In: Mayhall CG, ed.  Hospital Epidemiology and Infection Control, 3rd Edition.  Williams & Wilkins, Baltimore, 2004; Chapter 34: p.575-602.
  10. Murphy RP, Flaherty JP.  Contemporary Diagnosis and Management of HIV/AIDS.  2nd Edition. Handbooks in Healthcare, Newton, 2003.

Robert L. Murphy, MD
Professor of Medicine

  1. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH, Eng R, Hooton TM, Kerkering TM, Schultz M, van der Horst C, Hafner R.  A randomized comparative trial of atovaquone and dapsone for the prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection who are intolerant to trimethoprim and/or sulfonamides (CPCRA 034/ACTG 277).  N Engl J Med 1998; 339:1889-1895.
  2. Murphy RL, Gulick RM, DeGruttola V, D’Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR.  Treatment with amprenavir with or without zidovudine plus lamivudine in adults with human immunodeficiency virus infection.  J Infect Dis 1999;179:808-816.
  3. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, and Dusek A.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in HIV-1 infected individuals. J Infect Dis 1999;179:1116-23.
  4. Davey R, Murphy RL, Graziano F, Boswell S, Pavia A, Cancio M, Nadler J, Chaitt D, Dewar R, Sahner D, Duliege A-M, Capra W, Leong WP, Giedlin M, Lane C, Kahn J.  Immunologic improvement associated with HIV-1 suppression among persons receiving subcutaneous IL-2 treatment:  a randomized clinical trial.  JAMA 2000;284:183-189.
  5. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC, Benson C, Thompson M, Kessler H, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV infection:  48 week results.   AIDS 2001;15:F1-F9.
  6. Gulick RM, Smeaton LM, D’Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, and Murphy RL for the AIDS Clincical Trials Group 373 Study Team.  Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group Protocol 373.  J Infect Dis 2001;183:715-21.
  7. Schacker RW, Nguyen PL, Gatell J, Reilly C, Martinez E, Horban A, Bakawska E, Berzins B, van Leeuwen R, Wolinsky S, Haase AT, Murphy RL.  Persistent abnormalities in lymphoid tissues of HIV-infected persons successfully treated with antiretroviral therapy. J Infect Dis 2002;186:1092-7.
  8. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher R, Giordano M.  A dose-ranging, randomized, clinical trial of atazanavir in combination with lamivudine and stavudine in antretroviral-naïve subjects.  AIDS 2003; 17(18):2603-14.
  9. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl M, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D’Aquila RT, Vella S, Merigan TC, Hirsch MS.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.  N Engl J Med 2003;349:2293-2303. 
  10. Gulick RM, Ribaudo H, Shikuma CM, Lustgarten S, Squires K, Meyer WA, Acosta E, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt M, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR for the ACTG A5095 Protocol Team.  Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV infection:  AIDS Clinical Trials Group (ACTG) Study A5095.  N Engl J Med 2004; 350:32-43.

Gary Noskin, MD
Associate Professor of Medicine

  1. Noskin GA.  Vancomycin resistant enterococci:  clinical, microbiological and epidemiological features.  J Lab Clin Med  1997;130:14-20.
  2. Stosor V, Peterson LR, Postelnick M, Noskin GA.  Enterococcus faecium bacteremia:  Does vancomycin resistance make a difference?  Arch Intern Med 1998;158:522-527.
  3. Noskin G, Pietrelli L, Gurwith M, Bowden R.  Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.  Bone Marrow Transplant 1999;23:697-703.
  4. Noskin GA, Bednarz P, Reiner S, Suriano T, Peterson LR.  Persistent contamination of fabric covered furniture by vancomycin resistant enterococci:  implications for upholstery selection in hospitals.  Am J Infect Control 2000;28:311-313.
  5. Noskin GA, Peterson LR.  Engineering infection control through facility design.  Emerg Infect Dis 2001;7:354-357.
  6. Noskin GA, Suriano T, Collins S, Sesler S, Peterson LR.  Paenibacillus macerans pseudobacteremia resulting from contaminated blood culture bottles in a neonatal intensive care unit.  Am J Infect Control 2001;29:126-129.
  7. Prsytowsky J, Siddiqui F, Chosay J, Shinagarger DL, Millichap J, Peterson LR, Noskin GA.  Resistance to linezolid: characterization of mutations in rRNA and a comparison of their occurrence in vancomycin resistant enterococci.  Antimicrob Agents Chemother 2001;45:2154-2156.
  8. Suntharam N, Lankford MG, Trick WE, Peterson LR, Noskin GA.  Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagn Microbiol Infect Dis  2002;43:183-188.
  9. Price CS, Paule S, Noskin GA, Peterson LR.  Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia.  Clin Infect Dis 2003;37:921-928.
  10. Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, Noskin GA.  The epidemiology of prescribing errors.  The potential impact of computerized prescriber order entry.  Arch Intern Med 2004;164:785-792.

Frank Palella, MD
Assistant Professor of Medicine

  1. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, Aschman [Fisher] D, Holmberg S, the HIV Outpatient Study Investigators.  Declining Morbidity and Mortality in an Ambulatory HIV-Infected Population, New England Journal of Medicine 1998; 338;853-60.
  2. Holmberg S,  Moorman A, Von Bargen J, Palella F, et al, Possible Effectiveness of Clarithromycin and Rifabutin for Cryptosporidium Prophylaxis in HIV-Infected Patients, Journal of the American Medical Association (JAMA),1998;279:384-386.
  3. Palella FJ, Clinical Cohort Study – HOPS data, Infectious Diseases in Clinical Practice, 2001; 52-54.
  4. Palella F, Chmiel J, Moorman A, Durability and Predicators of Success of Highly Active Antiretroviral Therapy (HAART) for Ambulatory HIV-Infected Patients, AIDS 2002; 16:1-10.
  5. Palella FJ, Deloria-Knoll M. Chmiel JS, Moorman AC, Wood KC, Greenberg AE,   Holmberg SD, Survival Benefit of Initiating Antiretroviral Therapy in HIV-infected Persons in Different CD4+ Cell Strata, Annals of Internal Medicine. 2003; 138:620-626.
  6. Riddler SA, Smit E, Li R, Cole SR, Chmiel JS, Dobs A,  Palella FJ, Visscher B, Evans R, Kingsley LA, Serum Lipids and Antiretroviral Therapy among HIV-infected Men, Jounral of the American Medical Association (JAMA).  2003; 289:2978-2982.
  7. Holmberg S, Hamburger M, Moorman A, Wood K, Palella F,  Factors Associated with Maintenance of Long Term Plasma HIV (‘Viral Load’) Suppression, Clin Infect Dis 2003; 37:702-7.
  8. Uphold CR, Deloria-Knoll M, Palella FJ, Parada JP, Chmiel JS, Phan L, Bennet CL, US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era, Chest. 2004, 125(2):548-56.
  9. Palella FJ, Cole SR, Chmiel JS, Riddler SA, Visscher B, Dobs A, Williams C,  Anthropometrics and Examiner Reported Body Habitus Changes in the Multicenter AIDS Cohort Study, Clinical Infectious Diseases 2004: 38:903-7.
  10. Palella FJ, Chmiel JS, and Holmberg SD, HIV Survival Benefit Associated with Earlier Anitviral Therapy (letter), Annals of Internal Medicine  2004; 140: 579.

John Phair, MD
Professor Emeritus of Medicine

  1. Williams CF, Klinzman D, Yamashita TE, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D, Hess G, Stapleton JT. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004;350:981-990.
  2. An P, Vlahov D, Margolick JB, Phair J, O'Brien TR, Lautenberger J, O'Brien SJ, Winkler CA. A Tumor Necrosis Factor-alpha-Inducible Promoter Variant of Interferon-gamma Accelerates CD4+ T Cell Depletion in Human Immunodeficiency Virus-1-Infected Individuals. JID. 2003 Jul 15;188(2):228-31. Epub 2003 Jul 09.
  3. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, Funkhouser R, Fugate M, Theiler J, Hsu YS, Kunstman K, Wu S, Phair J, Erlich H, Wolinsky S. Advantage of rare HLA supertype in HIV disease progression. Nat Med. 2003 Jul;9(7):928-35.
  4. Modi WS, O'Brien TR, Vlahov D, Buchbinder S, Gomperts E, Phair J, O'Brien SJ, Winkler C. Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics. 2003 Jun;55(3):157-64. Epub 2003 Apr 25.
  5. Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, Rinaldo CR, Jacobson LP.  When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epid. 2003 Apr 15;157(8):738-46.
  6. Landay AL Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, Gonzalez CJ, Schnizlein-Bick CT, Evans T, Squires KE, Phair JP.  Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.  AIDS Research & Human Retroviruses 2002; 18:95-102.
  7. Chien PC, Cohen S, Kleeberger C, Giorgi J, Phair JP, Zolla-Pazner S, Hioe CE.  High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 Gycoprotein 120 are associated with faster disease progression.  JID 2002;186:205-13.
  8. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, Buchbinder S, Farrar WL, Modi W, O’Brien SJ, Winkler CA. Modulating influence on HIV/AIDS by interacting RANTES gene variants. PNAS 2002;99:10002-10007.
  9. Phair, JP, Mellors JW, Detels R, Margolick JB and Muñoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy.  AIDS 2002;16:2455-2459.
  10. Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, Phair J, Wolinsky S, Gabuzda D.  Persistence of dual-tropic HIV-1 in an individuals homozygous for the CCR5D32 allele. Lancet 2002;350:1832-1834.
  11. Tina Stosor, MD
    Assistant Professor of Medicine
  12. Paule SM, Trick WE, Tenover FC, Lankford M, Cunningham S, Stosor V, Cordell RL, Peterson LR.  Comparison of PCR assay to culture for surveillance detection of vancomycin-resistant enterococci.  J Clin Microbiol 2003, 41: 4805-7.
  13. Trick WE, Paule SM, Cunningham S, Cordell RL, Lankford M, Stosor V, Solomon SL, Peterson LR.  Detection of vancomycin-resistant enterococci before and after antimicrobial therapy: use of conventional culture and PCR.  Clin Infect Dis 2004; 38(6):780-6.
  14. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother 2000; 44:798-801.
  15. Dressel DC, Tornatore-Resucher MA, Boschman CR, Stosor V, Zembower T, Postelnick MJ, Noskin GA, Peterson LR. Synergistic effect of gentamicin plus ampicillin on enterococci with differing sensitivity to gentamicin: a phenotypic assessment of new NCLS guidelines. Diagnostic Microbiol and Inf Dis 1999;35:319-225.
  16. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrobial Agents & Chemotherapy 1999;43(8):2059-62.
  17. Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of Vancomycin-resistant Enterococci on fingertips and environmental surfaces. Infection Control Hosp Epidemiol 1995;16:577-81.
  18. Trakas K, Stosor V, Dietrich S, Mosher L, Warren JR. Persistent tuberculosis or specimen contamination? Arch of Path Laboratory Med 2000;124:902-3.
  19. Stosor V, Kruszynski J, Suriano T, Noskin GA, Peterson LR. Molecular epidemiology of vancomycin-resistant enterococci: a two-year perspective. Inf Control and Hosp Epidemiol 1999;20(10):653-659.
  20. Stosor V, Postelnick M, Peterson LR, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch of Int Med 1998; 158: 522-527.
  21. Stosor V, Wolinsky S. GB virus C and mortality from HIV infection. New Eng J Med 2001;345:761-2.

Sarah Sutton, MD
Instructor of Clinical Medicine

  1. Sutton, SH, Flherty, JP.  Infections associated with solid tumors.  Management of Infectious Complication sin Cancer Patients; 1998.
  2. Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P. Accelerated Neutrophil Apoptosis in the Acquired Immunodeficiency Syndrome. J. Clin. Investigation 1996;98(12):2714-19.

Michele Till, MD
Assistant Professor of Medicine

  1. Till M, MacDonell KB.  Myopathy with human immunodeficiency virus type 1 (HIV-1) infection:  HIV-1 or zidovudine?  Annal Int Med.  1990;13:7:492-494.
  2. Till  M, Lee N, Soper W, Murphy R.  Typhlitis in patients with human immunodeficiency virus type I (HIV‑1) infection.  Annal Int Med. 1992;116:998-1000. 
  3. Embretson J, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A, Haase AT.  Analysis of human immunodeficiency virus - infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single cell resolution.  Proc. Natl. Acad. Sci.1993;90:357-61.
  4. Patterson BK, Till M, Otto P, Goolsby C, Furtado M, McBride L, Wolinsky SM.  Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-drivin in situ hybridization and flow cytometry.  Science.  1993;260:976‑979.
  5. Del Priore G, Lee MJ, Barnes M, Garcia P, Till M.  The inadequacy of standard treatment of dysplasias in a woman with acquired immune deficiency syndrome.  International Journal of Gynecol. Obstet.  1994:47;273‑274.
  6. Anderson J, Clark RA, Watts HP, Till M, Arrastia C, Schuman P, Conh S, Young M, Bessen      L, Greenblatt R, Vogler M, Swindells S and Boyer P.   Idiopathic genital ulcers in women infected with the human immunodeficiency virus.  J Acquired Immune Def. Syndromes and Human Retrovirol. 1996;13:343-347.
  7. Hershow RC, Kalish L, Sha B, Till M, Cohen M.  Hepatitis C virus infection in Chicago Women with or at risk for HIV-1 infection: Evidence for sexual transmission. Sex Transm Dis. 1998;25(10):527-532
  8. Williams FS, Roure RM, Till M, Volger M, Del Priore G.  Treatment of Cervical Carcinoma in situ in HIV positive women. International  J Gynecol.and Obstet. 2000;71:136-139.
  9. Till M, Wixon R, Pertel P. Vancomycin-resistant Enterococcus faecium Osteomyelitis treated with Linezolid. Clinical Inf Dis. 2002; 34(10): 1412-14.
  10. Fraser TG, Till M.  Vertebral osteomyelitis due to Mycobacterium avium complex in a patient  with AIDS.  Infectious Diseases in Clinical Practice 2003; 11(7): 385-389.

Steven Wolinsky, MD
Samuel J. Sackett Professor and Chief

  1. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992; 255:1134-1137.
  2. Patterson BK, Till M, Otto P, Goolsby C, Furtado MR, McBride LJ, Wolinsky SM. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science. 1993; 260:976-979.
  3. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, Wolinsky SM. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 1994; 68:7467-7481.
  4. Wolinsky SM, Korber BT, Neumann, AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho, DD, Safrit JT and Koup RA. Adaptive evolution of human immunodeficiency virus type 1 during the natural course of infection. Science 1996; 272: 537-542.
  5. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 1998; 72:1552-1576.
  6. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazey RS, Notermans D, Little S, Danner SA, Richman DD, Havlir D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286:1353-1357.
  7. Furtado MF, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. Persistence of human immunodeficiency virus type-1 transcription in the peripheral blood cells of patients receiving potent antiretroviral therapy. New Eng. J. Med. 1999; 340:1614-1622.
  8. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn B, Wolinsky SM, Bhattacharya T. Timing the origin of the HIV-1 pandemic strains. Science. 2000; 288: 1789-1796.
  9. Barouch DH, Kunstman K, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, and Letvin NL. Eventual AIDS Vaccine Failure by CTL Escape. Nature. 2002; 415:335-9.
  10. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, Funkhouser R, Fugate M, Theiler J, Hsu M, Kunstman K, Wu S, Phair J, Erlich H, and Wolinsky S. HLA-A and HLA-B supertype alleles predict human immunodeficiency virus disease progression rate. Nature Medicine. 2003; 7:928-35.

Teresa Zembower, MD
Assistant Professor of Medicine

  1. Fraser TG, Stosor V, Wang Q, Allen A, Zembower TR.
    Evaluation of vancomycin use in a home healthcare setting. 
    Arch Intern Med (submitted for publication)
  2. Fraser TG, Zembower TR, Lynch P, Fryer J, Salvalaggio PR, Yeldandi AV, Stosor V.
    Cavitary Legionella pneumonia in a liver transplant recipient.
    Transpl Infect Dis. 2004 Apr;6:1-4.
  3. Verma A, Williams S, Trifilio S, Zembower T, Mehta J. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease. Bone Marrow Transplant. 2004 May;33(10):1065-6.
  4. Lankford MG, Zembower TR, Trick WE, Hacek DM, Noskin GA, Peterson LR. Influence of role models and hospital design on hand hygiene of healthcare workers.Emerg Infect Dis. 2003 Feb;9(2):217-23.
  5. Hacek DM, Bednarz P, Noskin GA, Zembower T, Peterson LR. Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program. J Clin Microbiol. 2001 Mar;39(3):1152-4.
  6. Warren JR, Farmer JJ 3rd, Dewhirst FE, Birkhead K, Zembower T, Peterson LR, Sims L, Bhattacharya M. Outbreak of nosocomial infections due to extended-spectrum beta-lactamase-producing strains of enteric group 137, a new member of the family Enterobacteriaceae closely related to Citrobacter farmeri and Citrobacter amalonaticus. J Clin Microbiol. 2000 Nov;38(11):3946-52.
  7. Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR, Noskin GA.The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance.
    Arch Intern Med. 2000 Oct 9;160(18):2819-22.
  8. Dressel DC, Tornatore-Reuscher MA, Boschman CR, Stosor V, Zembower T, Postelnick MJ, Noskin GA, Peterson LR.  Synergistic effect of gentamicin plus ampicillin on enterococci with differing sensitivity to gentamicin: a phenotypic assessment of NCCLS guidelines. Diagn Microbiol Infect Dis. 1999 Nov;35(3):219-25.
  9. Zembower TR, Noskin GA, Postelnick MJ, Nguyen C, Peterson LR. The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents. 1998 May;10(2):95-105. Review.
  10. Zembower T. Epidemiology of infectious complications in cancer patients.
    Cancer Treat Res. 1998;96:33-75. Review.